Apogee Therapeutics (APGE) Accumulated Expenses (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Accumulated Expenses data on file, last reported at $28.6 million in Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 7.68% year-over-year to $28.6 million in Q1 2026; TTM through Mar 2026 was $28.6 million, a 7.68% increase from a year earlier, with the FY2025 full-year figure at $23.2 million, down 4.43% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $28.6 million, up from $23.2 million in the prior quarter.
• Over the last five years, Accumulated Expenses for APGE reached as high as $29.6 million in Q3 2025 and fell as low as $2.2 million in Q3 2023.
• Historically, Accumulated Expenses has averaged $19.3 million across 5 years, with a median of $21.8 million in 2025.
• Across the five-year window, Accumulated Expenses soared 1139.44% in 2024 and decreased 4.43% in 2025, its largest moves.
• Year by year, Accumulated Expenses stood at $9.6 million in 2022, then surged by 81.07% to $17.3 million in 2023, then surged by 40.09% to $24.3 million in 2024, then retreated by 4.43% to $23.2 million in 2025, then rose by 23.28% to $28.6 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $28.6 million in Q1 2026, $23.2 million in Q4 2025, and $29.6 million in Q3 2025.